Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.
View/ Open
Date
2020-10-01ICR Author
Author
Barnes, DR
Rookus, MA
McGuffog, L
Leslie, G
Mooij, TM
Dennis, J
Mavaddat, N
Adlard, J
Ahmed, M
Aittomäki, K
Andrieu, N
Andrulis, IL
Arnold, N
Arun, BK
Azzollini, J
Balmaña, J
Barkardottir, RB
Barrowdale, D
Benitez, J
Berthet, P
Białkowska, K
Blanco, AM
Blok, MJ
Bonanni, B
Boonen, SE
Borg, Å
Bozsik, A
Bradbury, AR
Brennan, P
Brewer, C
Brunet, J
Buys, SS
Caldés, T
Caligo, MA
Campbell, I
Christensen, LL
Chung, WK
Claes, KBM
Colas, C
GEMO Study Collaborators,
EMBRACE Collaborators,
Collonge-Rame, M-A
Cook, J
Daly, MB
Davidson, R
de la Hoya, M
de Putter, R
Delnatte, C
Devilee, P
Diez, O
Ding, YC
Domchek, SM
Dorfling, CM
Dumont, M
Eeles, R
Ejlertsen, B
Engel, C
Evans, DG
Faivre, L
Foretova, L
Fostira, F
Friedlander, M
Friedman, E
Frost, D
Ganz, PA
Garber, J
Gehrig, A
Gerdes, A-M
Gesta, P
Giraud, S
Glendon, G
Godwin, AK
Goldgar, DE
González-Neira, A
Greene, MH
Gschwantler-Kaulich, D
Hahnen, E
Hamann, U
Hanson, H
Hentschel, J
Hogervorst, FBL
Hooning, MJ
Horvath, J
Hu, C
Hulick, PJ
Imyanitov, EN
kConFab Investigators,
HEBON Investigators,
GENEPSO Investigators,
Isaacs, C
Izatt, L
Izquierdo, A
Jakubowska, A
James, PA
Janavicius, R
John, EM
Joseph, V
Karlan, BY
Kast, K
Koudijs, M
Kruse, TA
Kwong, A
Laitman, Y
Lasset, C
Lazaro, C
Lester, J
Lesueur, F
Liljegren, A
Loud, JT
Lubiński, J
Mai, PL
Manoukian, S
Mari, V
Mebirouk, N
Meijers-Heijboer, HEJ
Meindl, A
Mensenkamp, AR
Miller, A
Montagna, M
Mouret-Fourme, E
Mukherjee, S
Mulligan, AM
Nathanson, KL
Neuhausen, SL
Nevanlinna, H
Niederacher, D
Nielsen, FC
Nikitina-Zake, L
Noguès, C
Olah, E
Olopade, OI
Ong, K-R
O'Shaughnessy-Kirwan, A
Osorio, A
Ott, C-E
Papi, L
Park, SK
Parsons, MT
Pedersen, IS
Peissel, B
Peixoto, A
Peterlongo, P
Pfeiler, G
Phillips, K-A
Prajzendanc, K
Pujana, MA
Radice, P
Ramser, J
Ramus, SJ
Rantala, J
Rennert, G
Risch, HA
Robson, M
Rønlund, K
Salani, R
Schuster, H
Senter, L
Shah, PD
Sharma, P
Side, LE
Singer, CF
Slavin, TP
Soucy, P
Southey, MC
Spurdle, AB
Steinemann, D
Steinsnyder, Z
Stoppa-Lyonnet, D
Sutter, C
Tan, YY
Teixeira, MR
Teo, SH
Thull, DL
Tischkowitz, M
Tognazzo, S
Toland, AE
Trainer, AH
Tung, N
van Engelen, K
van Rensburg, EJ
Vega, A
Vierstraete, J
Wagner, G
Walker, L
Wang-Gohrke, S
Wappenschmidt, B
Weitzel, JN
Yadav, S
Yang, X
Yannoukakos, D
Zimbalatti, D
Offit, K
Thomassen, M
Couch, FJ
Schmutzler, RK
Simard, J
Easton, DF
Chenevix-Trench, G
Antoniou, AC
Consortium of Investigators of Modifiers of BRCA and BRCA2,
Type
Journal Article
Metadata
Show full item recordAbstract
PURPOSE: We assessed the associations between population-based polygenic risk scores (PRS) for breast (BC) or epithelial ovarian cancer (EOC) with cancer risks for BRCA1 and BRCA2 pathogenic variant carriers. METHODS: Retrospective cohort data on 18,935 BRCA1 and 12,339 BRCA2 female pathogenic variant carriers of European ancestry were available. Three versions of a 313 single-nucleotide polymorphism (SNP) BC PRS were evaluated based on whether they predict overall, estrogen receptor (ER)-negative, or ER-positive BC, and two PRS for overall or high-grade serous EOC. Associations were validated in a prospective cohort. RESULTS: The ER-negative PRS showed the strongest association with BC risk for BRCA1 carriers (hazard ratio [HR] per standard deviation = 1.29 [95% CI 1.25-1.33], P = 3×10-72). For BRCA2, the strongest association was with overall BC PRS (HR = 1.31 [95% CI 1.27-1.36], P = 7×10-50). HR estimates decreased significantly with age and there was evidence for differences in associations by predicted variant effects on protein expression. The HR estimates were smaller than general population estimates. The high-grade serous PRS yielded the strongest associations with EOC risk for BRCA1 (HR = 1.32 [95% CI 1.25-1.40], P = 3×10-22) and BRCA2 (HR = 1.44 [95% CI 1.30-1.60], P = 4×10-12) carriers. The associations in the prospective cohort were similar. CONCLUSION: Population-based PRS are strongly associated with BC and EOC risks for BRCA1/2 carriers and predict substantial absolute risk differences for women at PRS distribution extremes.
Collections
Subject
GEMO Study Collaborators
EMBRACE Collaborators
kConFab Investigators
HEBON Investigators
GENEPSO Investigators
Consortium of Investigators of Modifiers of BRCA and BRCA2
Research team
Oncogenetics
Language
eng
Date accepted
2020-05-29
License start date
2020-10
Citation
Genetics in medicine : official journal of the American College of Medical Genetics, 2020, 22 (10), pp. 1653 - 1666
Publisher
ELSEVIER SCIENCE INC
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.
Feng, H; Gusev, A; Pasaniuc, B; Wu, L; Long, J; et al. (WILEY, 2020-07-01)Previous transcriptome-wide association studies (TWAS) have identified breast cancer risk genes by integrating data from expression quantitative loci and genome-wide association studies (GWAS), but analyses of breast cancer ... -
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.
Easton, DF; Lesueur, F; Decker, B; Michailidou, K; Li, J; et al. (BMJ PUBLISHING GROUP, 2016-05-01)BACKGROUND: BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, ... -
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Lakeman, IMM; van den Broek, AJ; Vos, JAM; Barnes, DR; Adlard, J; et al. (ELSEVIER SCIENCE INC, 2021-06-10)PURPOSE: To evaluate the association between a previously published 313 variant-based breast cancer (BC) polygenic risk score (PRS313) and contralateral breast cancer (CBC) risk, in BRCA1 and BRCA2 pathogenic variant ...